CHMP issues a positive opinion on the paediatric extension of berotralstat for the treatment of hereditary angioedema


Milan, 26 June 2026 – BioCryst Ireland, a Neopharmed Gentili company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the extension of the indication for berotralstat for the routine prophylaxis of recurrent attacks of hereditary angioedema (HAE) in children aged 2 to less than 12 years.

With this positive opinion, berotralstat has the potential to become the only oral therapy available for the prophylaxis of HAE in this age group of the paediatric population.

The CHMP’s opinion is based on the positive results of the APeX-P clinical trial, which demonstrated that berotralstat is generally well tolerated and capable of significantly and sustainably reducing the number of monthly attacks in paediatric patients up to 48 weeks.

Hereditary angioedema is a rare genetic disease that manifests with recurrent, painful episodes of swelling (edema), most commonly affecting the skin, the abdomen and the upper respiratory tract. The condition commonly manifests during childhood and puberty: approximatively half of patients experience their first attack before the age of 10, and the majority develop symptoms by the age of 18. Recurrent, unpredictable, and sometimes potentially life-threatening attacks have a significant impact on the quality of life of young patients, disrupting their daily lives and those of their families.

Berotralstat is already approved as a once-daily oral treatment (capsules) for the prevention of HAE attacks in adults and adolescents aged 12 years and older.

The new granule formulation has been developed to facilitate administration in children, offering an alternative to injectable or intravenous therapies.

The EMA CHMP’s positive opinion reinforces the company’s commitment to improving the management of HAE from the earliest stages of life, addressing a medical need that remains largely unmet within the paediatric population.

“We are pleased with the CHMP’s positive opinion on the paediatric extension of berotralstat for children aged 2 to less than 12 years, which marks an important step forward in expanding therapeutic options for hereditary angioedema”, said Alessandro Del Bono, CEO of Neopharmed Gentili. “This decision addresses a still unmet clinical need and paves the way for an evolution in the approach to the disease, making an oral therapy available for HAE prophylaxis from the earliest stages of life. By expanding access to a treatment that has already demonstrated benefits in adults and adolescents, we aim to help families manage the condition with greater confidence and continuity of care, reinforcing our commitment to improving the lives of people living with rare diseases”.